BRPI0607775A2 - conjugate, pharmaceutical composition, use of a compound, and method for treating or preventing disease - Google Patents
conjugate, pharmaceutical composition, use of a compound, and method for treating or preventing diseaseInfo
- Publication number
- BRPI0607775A2 BRPI0607775A2 BRPI0607775A BRPI0607775A BRPI0607775A2 BR PI0607775 A2 BRPI0607775 A2 BR PI0607775A2 BR PI0607775 A BRPI0607775 A BR PI0607775A BR PI0607775 A BRPI0607775 A BR PI0607775A BR PI0607775 A2 BRPI0607775 A2 BR PI0607775A2
- Authority
- BR
- Brazil
- Prior art keywords
- conjugate
- treating
- compound
- pharmaceutical composition
- preventing disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200500232 | 2005-02-16 | ||
PCT/EP2006/060007 WO2006087354A2 (en) | 2005-02-16 | 2006-02-16 | Insulinotropic agents conjugated with structurally well defined branched polymers |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0607775A2 true BRPI0607775A2 (en) | 2018-06-26 |
Family
ID=36609320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607775A BRPI0607775A2 (en) | 2005-02-16 | 2006-02-16 | conjugate, pharmaceutical composition, use of a compound, and method for treating or preventing disease |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1853321A2 (en) |
JP (1) | JP2008530178A (en) |
KR (1) | KR20070108180A (en) |
CN (1) | CN101123992A (en) |
AU (1) | AU2006215566A1 (en) |
BR (1) | BRPI0607775A2 (en) |
CA (1) | CA2601745A1 (en) |
MX (1) | MX2007009906A (en) |
RU (1) | RU2007128983A (en) |
WO (1) | WO2006087354A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23556A1 (en) * | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | POLYMER STRUCTURE SIMILAR TO DENDRÍMERO FOR THE OBTAINING OF CONJUGATES OF PHARMACEUTICAL INTEREST |
JP4991168B2 (en) * | 2006-03-10 | 2012-08-01 | 大阪瓦斯株式会社 | New dendrimer |
WO2008098693A2 (en) * | 2007-02-16 | 2008-08-21 | Bayer Healthcare Ag | Convergent synthesis of glp-1 |
AU2008244523B2 (en) * | 2007-04-23 | 2012-02-16 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
WO2008148839A2 (en) * | 2007-06-08 | 2008-12-11 | Ascendis Pharma As | Long-acting polymeric prodrugs of exendin |
US20130123460A1 (en) | 2010-04-30 | 2013-05-16 | Sanwa Kagaku Kenkyusho Co., Ltd. | Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability |
KR101702251B1 (en) * | 2012-11-29 | 2017-02-02 | 에스티팜 주식회사 | Bile acid oligomer conjugate for novel vesicular transport and use thereof |
ES2784603T3 (en) | 2015-06-02 | 2020-09-29 | Novo Nordisk As | Insulins with recombinant polar extensions |
MA43348A (en) | 2015-10-01 | 2018-08-08 | Novo Nordisk As | PROTEIN CONJUGATES |
JP7341061B2 (en) | 2016-11-22 | 2023-09-08 | エレクトロファイ, インコーポレイテッド | Particles containing therapeutic or diagnostic agents and their suspensions and methods of use |
WO2018185131A2 (en) | 2017-04-05 | 2018-10-11 | Novo Nordisk A/S | Oligomer extended insulin-fc conjugates |
AU2020214626A1 (en) | 2019-01-31 | 2021-09-16 | Elektrofi, Inc. | Particle formation and morphology |
CN110128526B (en) * | 2019-05-30 | 2021-07-23 | 江苏诺泰澳赛诺生物制药股份有限公司 | Long-acting exenatide derivative and salt thereof, and preparation method and application thereof |
AU2020344675A1 (en) | 2019-09-13 | 2022-03-31 | Elektrofi, Inc. | Compositions and methods for the delivery of therapeutic biologics for treatment of disease |
CN113896656B (en) * | 2021-10-28 | 2023-02-07 | 成都泰和伟业生物科技有限公司 | Preparation method of [2- [2- (Fmoc-amino) ethoxy ] acetic acid |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2353701A (en) * | 2000-01-11 | 2001-07-24 | Novo Nordisk A/S | Transepithelial delivery of glp-1 derivatives |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
AU2004212941B2 (en) * | 2003-02-14 | 2011-05-26 | Quanta Biodesign, Ltd | The selective and specific preparation of discrete PEG compounds |
JP2007501812A (en) * | 2003-08-08 | 2007-02-01 | ノボ ノルディスク アクティーゼルスカブ | Synthesis and application of new structurally well-defined branched polymers as binders for peptides |
MXPA06006745A (en) * | 2003-12-18 | 2006-08-18 | Novo Nordisk As | Novel glp-1 compounds. |
EP1771066A2 (en) * | 2004-07-13 | 2007-04-11 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1 |
-
2006
- 2006-02-16 CA CA002601745A patent/CA2601745A1/en not_active Abandoned
- 2006-02-16 MX MX2007009906A patent/MX2007009906A/en not_active Application Discontinuation
- 2006-02-16 EP EP06708301A patent/EP1853321A2/en not_active Withdrawn
- 2006-02-16 JP JP2007555611A patent/JP2008530178A/en not_active Withdrawn
- 2006-02-16 WO PCT/EP2006/060007 patent/WO2006087354A2/en active Application Filing
- 2006-02-16 CN CNA2006800053765A patent/CN101123992A/en active Pending
- 2006-02-16 RU RU2007128983/04A patent/RU2007128983A/en not_active Application Discontinuation
- 2006-02-16 KR KR1020077018995A patent/KR20070108180A/en not_active Application Discontinuation
- 2006-02-16 AU AU2006215566A patent/AU2006215566A1/en not_active Abandoned
- 2006-02-16 BR BRPI0607775A patent/BRPI0607775A2/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20070108180A (en) | 2007-11-08 |
CN101123992A (en) | 2008-02-13 |
WO2006087354A3 (en) | 2007-08-02 |
CA2601745A1 (en) | 2006-08-24 |
EP1853321A2 (en) | 2007-11-14 |
JP2008530178A (en) | 2008-08-07 |
RU2007128983A (en) | 2009-03-27 |
AU2006215566A1 (en) | 2006-08-24 |
WO2006087354A2 (en) | 2006-08-24 |
MX2007009906A (en) | 2007-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607775A2 (en) | conjugate, pharmaceutical composition, use of a compound, and method for treating or preventing disease | |
BRPI0818244A2 (en) | Compound, pharmaceutical composition, use of a compound, and method for treating a disorder or disease | |
BRPI0917458A2 (en) | compound, method of treating disease and conditions, pharmaceutical composition, method for treating or preventing disease, and use of a compound | |
BRPI0819799A2 (en) | Compound, intermediate, use of a compound, pharmaceutical composition, and method for preventing, treating or ameliorating a disease | |
BRPI0718587A2 (en) | USE OF A COMPOUND, COMPOUNDS, METHOD OF TREATING OR PREVENTING DISEASES, PROCESSES FOR THE PREPARATION OF COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | |
BRPI0907977A2 (en) | Compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease | |
BRPI0907974A2 (en) | Compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease | |
BRPI0618845A2 (en) | compound, pharmaceutical formulation, use of a compound, and methods for inhibiting bace activity and for treating or preventing a fir-related condition in a mammal | |
BRPI0816881A2 (en) | Compound, pharmaceutical composition, use of a compound, and methods for treating diseases or disorders and for preparing a compound. | |
BR122020011920A2 (en) | compound, pharmaceutical composition, method of treating a disease, use of a compound, and processes for preparing a compound, and for manufacturing a compound | |
BRPI0821299A2 (en) | Compound, process for preparing same, pharmaceutical composition, process for preparing same, use of a compound, and method for treating or reducing the risk of a disease or condition. | |
BRPI0717219A2 (en) | "immunogenic composition, method for treating or preventing disease, and use of an immunogenic composition." | |
BRPI0913585A2 (en) | compound, method for making a compound, pharmaceutical composition, use of a compound, and method for treating or preventing disorders | |
BRPI0912348A2 (en) | 3-aminocarbazole compound, pharmaceutical composition, method for preparing a 3-aminocarbazole compound, use of a 3-aminocarbazole compound, and method for treating or preventing disease | |
BRPI0815591A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, AND METHOD FOR TREATING A DISEASE, CONDITION OR DISTURBANCE. | |
BRPI0615163A2 (en) | compound, pharmaceutical composition, use of the compound, and methods for treating mglur5-mediated disorders and for inhibiting activation of mglur5 receptors | |
BRPI0612109A2 (en) | compound, methods of treating or preventing a disease, pharmaceutical formulation, and process for preparing a compound | |
BRPI0814688A2 (en) | compound, use of a compound, methods for producing an antiproliferative effect on a warm-blooded animal, and for treating disease, and, pharmaceutical composition | |
BRPI0908883A2 (en) | compound, pharmaceutical composition, use of a compound, and method for treating or preventing disease | |
BRPI0609802A2 (en) | compound, pharmaceutical composition and use of a compound | |
BRPI0917138A2 (en) | compound, methods for treating allergic diseases and other inflammatory conditions, allergic rhinitis, and for treating or preventing disease, pharmaceutical composition, use of a compound, and combination. | |
BRPI0819755A2 (en) | compound, pharmaceutical composition, processes for preparing a compound and a pharmaceutical composition, use of a compound, and method for treating or reducing the risk of an inflammatory disease or condition | |
BRPI0607545A2 (en) | compound, use of a compound of formula I or a pharmaceutically acceptable salt thereof, and pharmaceutical composition | |
BRPI0610514A2 (en) | compound, pharmaceutical composition, and method of treating a disorder | |
BRPI0720637A2 (en) | COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, STEREOISOMIC, TAUTOMERIC OR POLYMORPHIC FORM OF THEREOF, METHODS FOR TREATING A HOST AND INFECTION, PHARMACEUTICAL COMPOSITION, AND, USE OF THE COMPOUND |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO PARECER DA PROCURADORIA MEMO/INPI/PROC/NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO. |
|
B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: REFERENTE A PETICAO 020070114505/RJ DE 16/08/2007. |
|
B11M | Decision cancelled [chapter 11.13 patent gazette] | ||
B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2478 DE 03-07-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |